VistaGen Announces Pricing of Underwritten Offering of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
36
VistaGen Announces Pricing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock

SOUTH SAN FRANCISCO, CA --(Marketwired - December 11, 2017) - VistaGen Therapeutics, Inc. ( NASDAQ : VTGN ) ("VistaGen" or the "Company"), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system disorders, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock and warrants to purchase up to 10,000,000 shares of common stock at an offering price of $1.50 per share and related warrant. Each share of common stock is being sold together with a warrant to purchase one share of common stock. The warrants are immediately exercisable, have an exercise price of $1.50 per share and will terminate 5 years from the date of issuance. The gross proceeds of the offering are expected to be approximately $15 million, before deducting the underwriting discount and other estimated offering expenses.

Oppenheimer & Co. Inc. is acting as sole book-running manager and Chardan is acting as lead manager for the offering.

The closing of the offering is expected to occur on or about December 13, 2017, subject to the satisfaction of customary closing conditions.

VistaGen currently intends to use the net proceeds from the offering for research and development, primarily related to the AV-101 MDD Phase 2 Adjunctive Treatment Study, ordinary course working capital needs and other general corporate purposes.

The offering is being conducted pursuant to the Company's registration statement on Form S-1 (File No. 333-221009) previously filed with and subsequently declared effective by the Securities and Exchange Commission (the SEC) on December 8, 2017. A prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov .

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Copies of the prospectus, when available, relating to this offering may be obtained from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York, 10004, or by telephone at 212-667-8563, or e-mail at EquityProspectus@opco.com .

About VistaGen VistaGen Therapeutics, Inc. ( NASDAQ : VTGN ), is a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders. VistaGen's lead CNS product candidate, AV-101, is in Phase 2 development, initially as a new generation oral antidepressant drug candidate for major depressive disorder (MDD). AV-101's mechanism of action is fundamentally different from all FDA-approved antidepressants and atypical antipsychotics used adjunctively to treat MDD, with potential to drive a paradigm shift towards a new generation of safer and faster-acting antidepressants. AV-101 is currently being evaluated by the U.S. National Institute of Mental Health (NIMH) in a small Phase 2 monotherapy study in MDD being fully funded by the NIMH and conducted by Dr. Carlos Zarate Jr., Chief, Section on the Neurobiology and Treatment of Mood Disorders and Chief of Experimental Therapeutics and Pathophysiology Branch at the NIMH. VistaGen is preparing to launch a 180-patient Phase 2 study of AV-101 as an adjunctive treatment for MDD patients with an inadequate response to standard, FDA-approved antidepressants. Dr. Maurizio Fava of Harvard University will be the Principal Investigator of the Company's AV-101 MDD Phase 2 Adjunctive Treatment Study. AV-101 may also have the potential to treat multiple CNS disorders and neurodegenerative diseases in addition to MDD, including neuropathic pain, epilepsy, Huntington's disease, and Parkinson's disease levodopa-induced dyskinesia (PD LID) and other disorders where modulation of the NMDA receptors, activation of AMPA pathways and/or key active metabolites of AV-101 may achieve therapeutic benefit.

For more information, please visit www.vistagen.com and connect with VistaGen on Twitter , LinkedIn and Facebook .

Forward-Looking Statements The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the closing of the offering and the anticipated use of proceeds, risks related to the successful launch, continuation and results of the NIMH's Phase 2 (monotherapy) and/or the Company's planned Phase 2 (adjunctive therapy) clinical studies of AV-101 in MDD, and other CNS diseases and disorders, including neuropathic pain and PD LID, the potential for the Company's stem cell technology to produce NCEs, cellular therapies, regenerative medicine or bone marrow stem cells to treat any medical condition, including autoimmune disorders and cancer, allowance of patent applications and continued protection of its intellectual property, and the availability of substantial additional capital to support its operations, including the AV-101 clinical development activities described above. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. These and other risks and uncertainties are identified and described in more detail in VistaGen's filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC's website at www.sec.gov . VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.

Company Contact Mark A. McPartland VistaGen Therapeutics Inc. Phone: +1 (650) 577-3600 Email: IR@vistagen.com Investor Contact: Valter Pinto / Allison Soss KCSA Strategic Communications Phone: +1 (212) 896-1254/+1 (212) 896-1267 Email: VistaGen@KCSA.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 170

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Universal Haptics Protocol May Cut Integration Friction

Updated Category News Views 291

A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 20

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 139

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
Unishippers Climbs 18 Slots on 32.4% Sales Growth Run

Updated Category News Views 100

Thirty new franchise units can move the needle fast Unishippers did not inch its way up the Franchise Times Top 400; it put up a number that deserves a hard look. Sales rose 32.4% in 2025, the company added 30 franchise units, and the result was an 18-place jump to No. 81 on the 2026 ranking. In the shipping category, it was named the sales-growth leader. For a business...

Continue Reading
Knotch Bets Brands Need Answers, Not More Web Pages

Updated Category News Views 147

Pages are starting to look like expensive filing cabinets A website that cannot answer an agent may soon be expensive wallpaper. That is the blunt premise behind Knotch's Ace for Agents, launched Nov. 17, 2026, and frankly it lands because plenty of big companies have spent years piling pages atop pages until nobody can tell which claim is current. Knotch is pitching an...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 118

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Medical School Rejections Carry a Steep Price Tag Too

Updated Category News Views 86

A rejection letter can turn into a remarkably expensive piece of paper. BeMo Academic Consulting's new Medical School Admissions Trends Report argues that the damage from missing medical-school admission goes far beyond bruised confidence: applicants can spend thousands chasing another cycle, lose time entering practice, and, if they never get in, forgo what the report...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 15

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 14

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading

Top 5 Most Recently Viewed Articles

DoubleLine Income Solutions Fund Announces Monthly Distribution

Updated Category News Views 43

Back when the DoubleLine Income Solutions Fund made its rounds with a $0.11 per share distribution, traders were left scratching their heads over what it really meant for income stability. Sure, on paper it looked like a win—monthly distributions usually signal healthy cash flow—but the devil's in the details. The $0.11 Question: Solid Distribution or Just Smoke? That...

Continue Reading
Antiarrhythmic Drugs Market Growth and Future Projections

Updated Category News Views 115

Understanding the Future of the Antiarrhythmic Drugs Market The global antiarrhythmic drugs market is on a promising trajectory, with forecasts indicating a significant rise from USD 1.02 billion in 2023 to a remarkable USD 1.77 billion by 2032. This growth represents a compounded annual growth rate (CAGR) of 6.30% from 2024 to 2032. Increasing Demand Driven by Rising...

Continue Reading
Alvarez & Marsal Capital Partners Joins Forces with East Coast Power for Growth

Updated Category News Views 539

Alvarez & Marsal Capital Partners Forms Strategic Alliance Alvarez & Marsal Capital Partners has announced a pivotal strategic partnership with East Coast Power, marking an essential move to boost the development of electric utility services. This collaboration promises to provide the necessary investment aimed at accelerating East Coast Power's growth, with a clear focus...

Continue Reading
Sinclair Media Invites Applications for 2025 Diversity Scholarship

Updated Category News Views 126

Sinclair Announces Diversity Scholarship Program for Students Sinclair has exciting news — the company's annual Diversity Scholarship program is officially open for submissions for the upcoming academic year. This initiative has contributed nearly $400,000 to support students pursuing their education since it began in 2013. Empowering Diverse Voices in Broadcasting The...

Continue Reading
Traveling in Comfort: King's Hawaiian Unveils Softwear Line

Updated Category News Views 111

Experience Unmatched Comfort with King’s Hawaiian Softwear In an exciting new initiative, King’s Hawaiian invites travelers to embrace total comfort with their latest collection: the Softwear line. Designed to echo the signature fluffiness of the brand's beloved dinner rolls, these ultra-soft sweatshirts and sweatpants provide a perfect blend of comfort and style....

Continue Reading